MedicaidPrior AuthLow impact
Istodax (romidepsin) (New)
Humana·OH · Oncology, Hematology·Medicaid
Effective date
Mar 1, 2026
We identified it
Jun 24, 2026
Summary
Humana Medicaid Ohio has implemented a new prior authorization policy for Istodax (romidepsin), used to treat cutaneous T-cell lymphoma. The policy requires approval before dispensing this IV medication and has specific criteria including use as primary therapy or after at least one prior treatment.
Action Required
By March 1, 2026: Billing team must update prior authorization requirements for Istodax (romidepsin) IV solutions for Humana Medicaid Ohio patients. Ensure providers obtain prior auth by confirming drug is for cutaneous T-cell lymphoma treatment and meets criteria for primary biologic therapy OR patient has received at least one prior therapy. Claims will be denied without proper authorization.